Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Medtronic stock holds strong with steady target and Buy rating on sales growth

EditorNatashya Angelica
Published 24/05/2024, 16:18
© Reuters.
MDT
-

On Friday, TD Cowen maintained a positive outlook on Medtronic , Inc. (NYSE:MDT), reiterating a Buy rating and a stock price target of $95.00. The medical technology company reported fourth-quarter revenue and earnings per share (EPS) that surpassed Wall Street expectations. Medtronic's revenue reached $8.59 billion, and EPS was $1.46, outperforming the anticipated figures of $8.44 billion in revenue and $1.45 EPS.

The company experienced a 5.4% organic sales growth, exceeding its own forecast of 4-4.5%. This growth was driven by meeting or surpassing market-specific demand (MSD) across all four of its business units. Looking forward, Medtronic has set its fiscal year 2025 guidance to align with market estimates. The company is aiming for an organic sales growth of 4-5% and an EPS in the range of $5.40-$5.50.

Medtronic expects to see an acceleration in sales growth fueled by the launch of new products. Moreover, the company projects that its EPS growth will reach the high single digits (HSDs) by the end of the fiscal year. This positive performance aligns with the company's strategic plans and product development initiatives.

Investors have been keeping a close eye on Medtronic's financial health and growth trajectory. The latest earnings report and future guidance suggest that the company is on a solid path, with new product launches on the horizon potentially bolstering its market position.

The reaffirmed Buy rating and stock price target by TD Cowen reflect confidence in Medtronic's ability to continue its growth and deliver value to shareholders. The company's recent performance and optimistic outlook underscore its resilience and potential in the medical technology industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.